A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)

Key Points

• The lower-dose nilotinib tablet shows improved bioavailability compared to the existing capsule formulation.
• Key metrics indicate that the absorption rate of the tablet is 20% higher than that of the capsule during initial digestion.
• Analysis of pharmacokinetics reveals differences in how the body processes the two forms of nilotinib.
• Understanding these differences could enhance treatment strategies and patient satisfaction with dosing options.

Abstract